{
    "organizations": [],
    "uuid": "2c163118a8fe01ef4b69d53e5d706f64193cad01",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aerie-pharmaceuticals-submits-nda/brief-aerie-pharmaceuticals-submits-nda-to-u-s-fda-for-roclatantm-idUSASC0A273",
    "ord_in_thread": 0,
    "title": "BRIEF-Aerie Pharmaceuticals Submits NDA To U.S. FDA For Roclatantm",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 15 (Reuters) - Aerie Pharmaceuticals Inc:\n* AERIE PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR ROCLATANTM (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005%\n* AERIE PHARMACEUTICALS - EXPECTED FDA REVIEW PERIOD FOR ROCLATAN NDA IS TEN MONTHS\n* AERIE PHARMACEUTICALS INC - NDA SUBMITTED AS A 505(B)(2) WITH AN EXPECTED TEN-MONTH FDA REVIEW Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ",
    "published": "2018-05-15T19:00:00.000+03:00",
    "crawled": "2018-05-16T18:48:27.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "aerie",
        "pharmaceutical",
        "inc",
        "aerie",
        "pharmaceutical",
        "submits",
        "new",
        "drug",
        "application",
        "food",
        "drug",
        "administration",
        "roclatantm",
        "ophthalmic",
        "solution",
        "aerie",
        "pharmaceutical",
        "expected",
        "fda",
        "review",
        "period",
        "roclatan",
        "nda",
        "ten",
        "month",
        "aerie",
        "pharmaceutical",
        "inc",
        "nda",
        "submitted",
        "b",
        "expected",
        "fda",
        "review",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}